What does the evidence say about Chlorella Cardiometabolic Markers Randomized Trial?

The current Migaku evidence database contains 1 reusable source document for Chlorella Cardiometabolic Markers Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Cardiovascular diseases remain a global challenge, and lipid-associated biomarkers can predict cardiovascular events. [Santos HO (2020); evidence level 4] - However, evidence suggests that plant sources of ALA are associated with favourable cardiometabolic status. [Santos HO (2020); evidence level 4] - ALA supplementation, or increased consumption of ALA-rich foodstuffs, combined with reduced omega-6 (n6) PUFAs intake, could improve the n3/n6 ratio and improve cardiometabolic and lipid profile. [Santos HO (2020); evidence level 4] - Extensive research on cardiovascular benefits of omega-3 polyunsaturated fatty acids (n3-PUFAs) is geared towards fish oil supplementation and fish-rich diets. [Santos HO (2020); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.